stockrow
Friday 6 November 2026
Export AMLX’s income statement to Excel — free account
Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
27.79
1.61
−5.48%
Follow AMLX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | 6 | 5 | — | — | — |
P/E ratio |
— | 0.00 | 20.51 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | 2.95 | 2.64 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | (2.95) | 8.11 | 23.63 | — | — | — |
P/FCF ratio |
— | 0.00 | 94.26 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | (9.69) | 8.85 | 6.25 | 0.68 | (30.71) | — |
Beneish M-Score |
— | — | 13.35 | — | — | — | — |
P/Operating CF |
— | (4.37) | 74.27 | (42.35) | (4.21) | (4.21) | — |
P/B ratio |
— | 1.56 | 2.32 | 6.18 | 0.00 | 0.00 | — |
Price to Tangible BV |
— | 1.56 | 2.32 | 6.18 | 0.00 | 0.00 | — |
EV/Sales |
— | 0.94 | 1.67 | 0.00 | 0.00 | 0.00 | — |
EV/EBITDA |
— | 0.00 | 21.25 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | (0.49) | 53.41 | (9.78) | (0.33) | (0.33) | — |
EV/FCF |
— | (0.40) | 59.61 | (9.64) | (0.32) | (0.32) | — |
Quick Ratio |
13.98 | 6.23 | 5.01 | 7.77 | 5.53 | 1.76 | — |
Current Ratio |
14.27 | 6.67 | 5.66 | 8.20 | 6.03 | 1.86 | — |
Net Debt/EBITDA |
2.00 | 0.55 | (12.40) | 1.71 | 1.16 | 0.29 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.10% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | — |
Asset Turnover |
0.00 | 0.25 | 0.84 | 0.09 | 0.00 | 0.09 | — |
Operating CF/Net income |
0.85 | 0.56 | 0.24 | 0.91 | 0.85 | 0.87 | — |
Capex/Depreciation |
0.03 | 4.06 | 0.14 | 1.61 | (2.04) | (151.00) | — |
Interest Coverage |
— | — | — | — | — | (17.05) | — |
| (61.59%) | (100.88%) | 12.73% | (209.43%) | 80.71% | 0.00% | — | |
| (55.00%) | (84.87%) | 10.84% | (79.82%) | (146.90%) | (599.55%) | — | |
ROIC |
0.00% | 0.00% | 39.07% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(48.04%) | (186.28%) | 12.79% | (58.67%) | (99.89%) | (654.08%) | — |
Average Days of Receivables |
0.00 | 1.87 | 38.39 | 251.31 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 119.13% | 33.66% | 420.38% | 15,452.63% | 3,783.69% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 130.86% | 49.47% | 571.88% | 13,660.70% | 2,317.08% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 37.81% | 9.76% | 97.68% | 1,100.35% | 37.38% | — |
Graham Net Nets |
— | 0.62 | 0.38 | 0.16 | 0.74 | 0.74 | — |
Graham Number |
— | 0.00 | 10.29 | 0.00 | 83.03 | 0.00 | — |
Earnings Yield |
— | (117.46%) | 4.88% | (9.53%) | (73.88%) | (73.88%) | — |
Free Cash Flow Yield |
— | (79.20%) | 1.06% | (8.67%) | (63.15%) | (63.15%) | — |
Revenue per Share |
0.00 | 1.28 | 5.66 | 0.38 | 0.04 | 0.11 | — |
Operating CF per Share |
(1.30) | (2.46) | 0.18 | (3.07) | (11.36) | (6.04) | — |
Capex per Share |
0.00 | (0.53) | (0.02) | (0.04) | (0.05) | (0.02) | — |
Free Cash Flow per Share |
(1.31) | (2.99) | 0.16 | (3.12) | (11.41) | (6.06) | — |
Cash per Share |
3.35 | 2.59 | 5.52 | 5.93 | 14.59 | 2.12 | — |
Shareholders Equity per Share |
3.23 | 2.42 | 6.45 | 5.82 | 13.39 | 0.88 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.23 | 2.42 | 6.45 | 5.82 | 13.39 | 0.88 | — |
Free Cash Flow |
(123.48) | (204.01) | 10.68 | (182.40) | (75.15) | (36.85) | — |
Working Capital |
300.98 | 161.03 | 382.62 | 335.52 | 87.56 | 6.31 | — |
Capital Expenditures |
(0.14) | (36.36) | (1.24) | (2.53) | (0.35) | (0.15) | — |
Net Current Asset Value |
296.29 | 160.56 | 380.64 | 331.29 | 87.52 | 4.87 | — |
EV/EBIT |
— | 0.00 | 16.41 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.42 | 0.00 | 0.11 | 1.24 | 0.23 | — |
Price to Operating Income |
— | 0.00 | 25.94 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
(16.13) | (9.32) | (3.30) | (0.60) | 0.37 | 0.01 | — |
Cash ROIC |
(19.84%) | (59.78%) | 1.33% | (26.53%) | (40.78%) | (187.63%) | — |
Accounts Receivable Turnover |
0.00 | 4.31 | 13.76 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 9.97 | 1.80 | 0.56 | 0.00 | — | — |
Inventory Turnover |
— | 0.00 | 1.06 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 8.61 | 316.51 | 763.05 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | 0.00 | 549.82 | 1,191.34 | — | — | — |
Average Receivables |
0.27 | 20.25 | 27.68 | — | — | — | — |
Average Payables |
3.23 | 12.50 | 14.16 | 5.31 | 3.99 | — | — |
Average Inventory |
— | — | 24.05 | — | — | — | — |
Average Assets |
263.14 | 355.54 | 454.45 | 248.53 | 59.86 | 7.05 | — |
Average Common Equity |
235.01 | 299.10 | 387.02 | 94.72 | (108.95) | — | — |
Columns are period end dates